DrugPatentWatch

Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Generic Name: albuterol sulfate; ipratropium bromide

Summary for Generic Name: albuterol sulfate; ipratropium bromide

Tradenames:4
Patents:23
Applicants:9
NDAs:10
Drug Master File Entries: see list34
Suppliers: see list6

Pharmacology for Ingredient: albuterol sulfate; ipratropium bromide

Clinical Trials for: albuterol sulfate; ipratropium bromide

Ipratropium or Salbutamol Sulphate Alone or Combination Therapy Salbutamol and Ipratropium in Patients With COPD
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Budesonide Inhalation Suspension for Acute Asthma in Children
Status: Completed Condition: Asthma; Acute Asthma; Reactive Airway Exacerbation

The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia
Status: Recruiting Condition: Respiratory Disease in Familial Dysautonomia

Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis
Status: Terminated Condition: Asthma

Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm
Status: Completed Condition: Asthma

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients
Status: Completed Condition: COPD

Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.
Status: Completed Condition: Pulmonary Disease, Chronic Obstructive

Study to Assess the Efficacy of Ipratropium Bromide Associated With High Dose Salbutamol by Repeated Nebulisation Versus Repeat Nebulisation of Salbutamol Alone, in Acute Asthmatic Attacks in Young Children
Status: Terminated Condition: Asthma

A Crossover Study in the Treatment of Patients With COPD
Status: Completed Condition: Chronic Obstructive Pulmonary Disease

Courtesy of ClinicalTrials.org
See more clinical trials for this drug

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Boehringer Ingelheim
COMBIVENT
albuterol sulfate; ipratropium bromide
AEROSOL, METERED;INHALATION020291Oct 24, 1996RXYes5,603,918<disabled>
Apotex Inc
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION077117Dec 31, 2007DISCNNo<disabled>
Cipla Ltd
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION077559Dec 31, 2007RXNo<disabled>
Nephron
ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE
albuterol sulfate; ipratropium bromide
SOLUTION;INHALATION076749Dec 31, 2007RXNo<disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology

`abc